Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Han ES, et al. Among authors: darcy km. Gynecol Oncol. 2010 Dec;119(3):484-90. doi: 10.1016/j.ygyno.2010.08.016. Epub 2010 Sep 25. Gynecol Oncol. 2010. PMID: 20870280 Free PMC article. Clinical Trial.
Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn DE. Burger RA, et al. Among authors: darcy km. Cancer. 2004 Jul 1;101(1):106-15. doi: 10.1002/cncr.20314. Cancer. 2004. PMID: 15221995 Free article. Clinical Trial.
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N; Gynecologic Oncology Group. Garcia AA, et al. Among authors: darcy km. Gynecol Oncol. 2005 Mar;96(3):810-7. doi: 10.1016/j.ygyno.2004.11.037. Gynecol Oncol. 2005. PMID: 15721430 Clinical Trial.
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Schilder RJ, et al. Among authors: darcy km. Clin Cancer Res. 2005 Aug 1;11(15):5539-48. doi: 10.1158/1078-0432.CCR-05-0462. Clin Cancer Res. 2005. PMID: 16061871 Clinical Trial.
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Garcia AA, Blessing JA, Darcy KM, Lenz HJ, Zhang W, Hannigan E, Moore DH. Garcia AA, et al. Among authors: darcy km. Gynecol Oncol. 2007 Mar;104(3):572-9. doi: 10.1016/j.ygyno.2006.09.002. Epub 2006 Oct 17. Gynecol Oncol. 2007. PMID: 17049588 Free PMC article. Clinical Trial.
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD; Gynecologic Oncology Group. McMeekin DS, et al. Among authors: darcy km. Gynecol Oncol. 2007 May;105(2):508-16. doi: 10.1016/j.ygyno.2007.01.019. Epub 2007 Feb 15. Gynecol Oncol. 2007. PMID: 17306350 Free PMC article. Clinical Trial.
154 results